Efficacy and safety of lacosamide in patients with erythromelalgia due to SCN9A gene mutation

Efficacy and safety of lacosamide in patients with erythromelalgia due to SCN9A gene mutation - Efficacy and safety of lacosamide in patients with erythromelalgia due to SCN9A gene mutation

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028778

Enrollment

Registered

2017-08-23

Start date

2017-08-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

erythromelalgia

Interventions

The administration of lacosamide is started on 50 mg/day, the dose is increased by 50 mg/ day each week until 200 mg/day for a maintenance dose. It can be increased up to 400 mg / day without side eff

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: A case of erythromelalgia due to SCN9A gene mutation.

Exclusion criteria

Exclusion criteria: A case with kidney dysfunction A case with significant ECG abnormality A Case who is considered by doctor to be inappropriate for administration of lacosamide.

Design outcomes

Primary

Measure	Time frame
Amount of change in scoring below 8 weeks after starting lacosamide administration Pain Intensity Numerical Rating Scale Daily sleep interference scale	—

Countries

Japan

Contacts

Public ContactSayaka Yamaguchi

University of the Ryukyus Hospital Dermatology

sayaka-y@med.u-ryukyu.ac.jp098-895-1153

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026